Chesapeake IRB

Chesapeake IRB, Schulman IRB merge to create Advarra

Wednesday, November 8, 2017

Chesapeake IRB and Schulman IRB, two respected institutional review boards (IRBs), have combined to create Advarra, a premier provider of IRB, institutional biosafety committee (IBC) and research compliance services in North America. The new organization will leverage mutual strengths in technology, regulatory expertise and customer service to serve the increasingly complex needs associated with research.

[Read More]

New NIH policy ties funding approval to single IRB review

Saturday, October 1, 2016

The wait is over. For the past few years researchers and their respective research institutions have faced the distinct probability that the regulations to protect individuals who agree to volunteer in a research study will be significantly changed. After much discussion on proposed changes to the Common Rule in the Notice of Proposed Rulemaking (NPRM), the Department of Health and Human Services (HHS) is poised to publish a Final Rule. “We expect to publish the Final Rule before the end of the year,” according to an HHS spokesperson.

[Read More]

Big Data in clinical trials: Promise and pitfalls

Monday, August 15, 2016

Privacy versus medical progress. Proprietary ownership versus public information. Cost-effectiveness versus unnecessary burdens. Welcome to the swirl of opinions and emotions around Big Data and its potential—or not—in the clinical trials industry.

[Read More]

Survey: SCORR to present industry thoughts on Big Data, recruitment, confidentiality

Friday, June 10, 2016

SCORR Marketing, a global health science marketing and communications firm, and Chesapeake IRB, a technology-enabled independent institutional review board (IRB) serving the clinical research industry, will present “Does ‘Big Data’ for Enhanced Recruiting Invade Patient Confidentiality?” and “The Internet of Things and Clinical Research: Privacy, Security and Ethical Aspects” at the Drug Information Association (DIA) Annual Meeting in Philadelphia.

[Read More]

IPOs in the CRO market remain steady

Monday, April 18, 2016

InVentiv Health has filed paperwork for an initial public offering (IPO) worth up to $100 million, following in the footsteps of three other large private equity-backed CROs that have gone public in recent years. Analysts see strong financial activity on the horizon for the CRO industry.

[Read More]